Treatment of slow-channel congenital myasthenic syndrome in a Thai family with fluoxetine
Issued Date
2022-02-01
Resource Type
ISSN
09675868
eISSN
15322653
Scopus ID
2-s2.0-85122237680
Pubmed ID
34999496
Journal Title
Journal of Clinical Neuroscience
Volume
96
Start Page
85
End Page
89
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Clinical Neuroscience Vol.96 (2022) , 85-89
Suggested Citation
Dejthevaporn C. Treatment of slow-channel congenital myasthenic syndrome in a Thai family with fluoxetine. Journal of Clinical Neuroscience Vol.96 (2022) , 85-89. 89. doi:10.1016/j.jocn.2021.12.016 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/86167
Title
Treatment of slow-channel congenital myasthenic syndrome in a Thai family with fluoxetine
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
The slow-channel congenital myasthenic syndrome is an autosomal dominant neuromuscular disorder caused by mutations in different subunits of the acetylcholine receptor. Fluoxetine, a common antidepressant and long-lived open-channel blocker of acetylcholine receptor, has been reported to be beneficial in the slow-channel congenital myasthenic syndrome. Here we report a prospective open label study of fluoxetine treatment in some affected members of a Thai family with slow-channel congenital myasthenic syndrome caused by a novel p.Gly153Ala (c.518G > C) mutation in CHRNA1 in the AChR α subunit. These patients showed significant clinical improvement following fluoxetine treatment but their respiratory function responded variably.